

Date: 12/02/2019

To

Deputy Manager

Dept. of Corporate Services,

BSE Limited

P J Towers, Dalal Street,

Fort, MUMBAI - 400001

Sub: Outcome of Board Meeting held on 12th February, 2019.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 12th February,2019 has approved Unaudited financial results for the quarter ended on 31st December,2018. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Unaudited Financial results for the quarter ended 31st December,2018 along with Limited Review Report issued by the Statutory Auditors of the company.

Further, please find enclosed herewith the Revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information u/r Reg. 8(1), Chapter IV, which has been amended to incorporate additional clauses mandated by the SEBI (Prohibition of Insider Trading) Amendment Regulations 2018, as approved by the Board of Directors in its Meeting held today

The Meeting started at 5.00 PM and ended at 7:30 PM This is for your record and reference.

Thanking you,

Yours faithfully, For Vivo Bio Tech Limited

M Kalyan Ramu

Whole Time Director

DIN: 02012580

Statement of Unaudited Financial Results for the Quarter ended on 31st December, 2018 Rs.in Lakhs							
		QUARTER ENDED			Nine Months Ended		Year Ended
S.No.	PARTICULARS	31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
I	Revenue from operations	1,442.10	1,406.45	1,206.98	4,206.84	3,467.15	4,700.12
II	Other income	-	-	-	0.46	12.74	13.35
III	Total Income	1,442.10	1406.45	1206.98	4207.31	3479.89	4713.47
IV	Expenses						
	a) (Increase)/decrease in stock in trade and						
	WIP	88.41	(172.32)	(50.01)	(144.31)	-393.13	(302.77)
	b) Consumption of Raw materials	-	-	-	-	-	-
	c) Purchases	187.74	478.25	294.43	1,022.59	933.56	1,259.60
	d) Employees Cost	231.15	219.27	178.31	657.19	585.07	758.52
	e) Depreciation and amortisation	134.56	128.79	144.66	379.33	371.92	463.94
	f) Finance Cost	65.32	68.84	63.69	200.57	174.91	236.75
	g)Administrative Expenditure	611.32	490.48	467.83	1,595.67	1,519.38	1,896.64
	Total	1,318.50	1213.32	1098.91	3711.03204	3191.71	4312.68
V	Profit before tax	123.60	193.13	108.08	496.2744587	288.19	400.78
VI	Tax Expense						
	a. Current Tax	41.48	42.18	22.50	118.20	54.91	110.42
	b. Deffered tax	(44.14)	(95.60)	10.47	(143.86)	2.67	(21.94)
VII	Profit (Loss) for the period (V- VI)	126.26	246.55	75.11	521.94	230.60	312.30
VIII	Other Comprehensive Income						
	a.i.Items that will not be reclassified to profit or						
	loss (Net of Tax)	-	-	0.28	-	0.84	1.13
IX	Total other Comprehensive Income	-	-	0.28	-	0.84	1.13
Х	Total Comprehensive Income(VII + IX)	126.26	246.55	75.39	521.94	231.44	313.43
XI	Paid Up Share Capital (Face value of Rs.10/-)	995.05	995.05	935.05	995.05	935.05	985.05
XII	Earnings per equity share:						
	1)Basic	1.27	2.48	0.81	5.25	2.48	3.17
	2)Diluted	0.99	1.93	0.81	4.09	2.48	2.36

Place: Hyderabad Dated:12/02/2019

For VIVO BIO TECH LTD

M.KALYAN RAM WHOLE TIME DIRECTOR DIN:02012580



Notes

- 1. The Company has adopted IND AS with effect from 01st April,2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34, prescribed under Section 133 of the Companies Act. 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34.
- The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 12th February,2019.
- 3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
- 4. The Standalone Financial Results for quarter ended 31st December, 2018 are reviewed by the statutory auditors as per Regiulation.33 of SEBI(Listing Obligations and disclosure Requirements) Regulations, 2015
- 5. An Extract of the detailed format of unaudited financial results filed with stock exchange under Regulation 33 of SEBI(Listing obligations and Disclosure Requirements) Regulations, 2015 will be published in Newspaper.
- 6. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Place: Hyderabad


Date: 12th February,2019

For Vivo Bio Tech Limited

M Kalyan Ram

Whole Time Director W

DIN: 02012580



Tel. : (91-40) 2311 9499

E-mail: pcnassociates@yahoo.com

LIMITED REVIEW REPORT

To The Board of Directors M/s. Vivo Bio Tech Limited Hyderabad

Limited Review Report for the Quarter and Nine months ended 31stDecember, 2018

- 1. We have reviewed the accompanying statement of unaudited financial results of M/s. Vivo Bio Tech Limited for the quarter ended 31stDecember, 2018 and year to date from April 1st 2018 to December 31st 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
- 2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 12th February, 2019. Our responsibility is to issue a report on these financial statements based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates. Chartered Accountants

FRN; 016016S

Chandra Babu M

Partner M.No. 227849

Place: Hyderabad

Date: 12th February,2019.



Approved by the Board of Directors on 15th May, 2015 and further revised on 12th February, 2019

CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION [As envisaged under Regulation 8 (1) of SEBI (Prohibition of Insider Trading) Regulations, 2015]

Principles of Fair Disclosure for purposes of Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information.

The Company shall adhere to the following principles in order to ensure timely and adequate disclosure of Price Sensitive Information with respect to it or its securities which is likely to affect price of the securities:

- 1. The Company will make prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.
- 2. The Company will make, uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
- 3. The Company Secretary will be chief investor relations officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
- 4. The Company will make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
- 5. The Company will provide appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
- 6. The Company will ensure that, information, if any, shared with analysts and research personnel is not unpublished price sensitive information.
- 7. The Company will make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the website of the Company to ensure official confirmation and documentation of disclosures made.
- 8. The Company will handle all unpublished price sensitive information on a need-to-know basis.

Vivo Bio Tech Ltd.
Your Drug Discovery Partner

9. Sharing of information with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals, other advisors or consultants, shall be considered as "legitimate purposes" for the purpose of sharing unpublished price sensitive information in the ordinary course of business by an insider,

provided that such sharing has not been carried out to evade or circumvent the prohibitions

of the PIT regulations.

10. A structured digital database shall be maintained containing the names of such persons

or entities as the case may be with whom information is shared for legitimate purposes

along with the Permanent Account Number or any other identifier authorized by law where

Permanent Account Number is not available. Adequate and effective system of internal

controls will also be laid out to ensure the compliance of maintenance of a digital database

for sharing the information for said legitimate purposes.

11. Any person in receipt of unpublished price sensitive information pursuant to a

"legitimate purpose" shall be considered an "insider" for purposes of SEBI PIT regulations

and such persons are also required to ensure the confidentiality of unpublished price

sensitive information shared with them, in compliance with SEBI PIT Regulations.

(Note: Clauses 9 to 11 incorporated pursuant to SEBI (Prohibition of Insider Trading)

(Amendment) Regulations, 2018 shall come into effect from 1 April, 2019.)